Literature DB >> 33506602

Neurolysin substrates bradykinin, neurotensin and substance P enhance brain microvascular permeability in a human in vitro model.

Abraham J Al-Ahmad1, Iqra Pervaiz1, Vardan T Karamyan1.   

Abstract

Increased brain microvascular permeability and disruption of blood-brain barrier (BBB) function are among hallmarks of several acute neurodegenerative disorders, including stroke. Numerous studies suggest the involvement of bradykinin (BK), neurotensin (NT) and substance P (SP) in BBB impairment and oedema formation after stroke; however, there is paucity of data in regard to the direct effects of these peptides on the brain microvascular endothelial cells (BMECs) and BBB. The present study aimed to evaluate the direct effects of BK, NT and SP on the permeability of BBB in an in vitro model based on human induced pluripotent stem cell (iPSC)-derived BMECs. Our data indicate that all three peptides increase BBB permeability in a concentration-dependent manner in an in vitro model formed from two different iPSC lines (CTR90F and CTR65M) and widely used hCMEC/D3 human BMECs. The combination of BK, NT and SP at a sub-effective concentration also resulted in increased BBB permeability in the iPSC-derived model indicating potentiation of their action. Furthermore, we observed abrogation of BK, NT and SP effects with pretreatment of pharmacological blockers targeting their specific receptors. Additional mechanistic studies indicate that the short-term effects of these peptides are not mediated through alteration of tight-junction proteins claudin-5 and occludin, but likely involve redistribution of F-actin and secretion of vascular endothelial growth factor. This is the first experimental study to document the increased permeability of the BBB in response to direct action of NT in an in vitro model. In addition, our study confirms the expected but not well-documented, direct effect of SP on BBB permeability and adds to the well-recognised actions of BK on BBB. Lastly, we demonstrate that peptidase neurolysin can neutralise the effects of these peptides on BBB, suggesting potential therapeutic implications.
© 2021 British Society for Neuroendocrinology.

Entities:  

Keywords:  blood-brain barrier; microvascular permeability; neuropeptide; oedema formation; peptidase neurolysin

Mesh:

Substances:

Year:  2021        PMID: 33506602      PMCID: PMC8166215          DOI: 10.1111/jne.12931

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  89 in total

1.  Structure of neurolysin reveals a deep channel that limits substrate access.

Authors:  C K Brown; K Madauss; W Lian; M R Beck; W D Tolbert; D W Rodgers
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

Review 2.  Soluble metalloendopeptidases and neuroendocrine signaling.

Authors:  Corie N Shrimpton; A Ian Smith; Rebecca A Lew
Journal:  Endocr Rev       Date:  2002-10       Impact factor: 19.871

3.  Methoxyluteolin Inhibits Neuropeptide-stimulated Proinflammatory Mediator Release via mTOR Activation from Human Mast Cells.

Authors:  Arti B Patel; Theoharis C Theoharides
Journal:  J Pharmacol Exp Ther       Date:  2017-04-12       Impact factor: 4.030

4.  Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process.

Authors:  Jill Donelan; William Boucher; Nikoletta Papadopoulou; Michael Lytinas; Dean Papaliodis; Paul Dobner; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

5.  Hyaluronan impairs the barrier integrity of brain microvascular endothelial cells through a CD44-dependent pathway.

Authors:  Abraham J Al-Ahmad; Ronak Patel; Sean P Palecek; Eric V Shusta
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-28       Impact factor: 6.200

6.  Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium.

Authors:  Pasquale Annunziata; Chiara Cioni; Riccardo Santonini; Eugenio Paccagnini
Journal:  J Neuroimmunol       Date:  2002-10       Impact factor: 3.478

7.  Isogenic blood-brain barrier models based on patient-derived stem cells display inter-individual differences in cell maturation and functionality.

Authors:  Ronak Patel; Shyanne Page; Abraham Jacob Al-Ahmad
Journal:  J Neurochem       Date:  2017-05-14       Impact factor: 5.372

8.  Blockade of mast cell histamine secretion in response to neurotensin by SR 48692, a nonpeptide antagonist of the neurotensin brain receptor.

Authors:  L A Miller; D E Cochrane; R E Carraway; R S Feldberg
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

9.  The proinflammatory peptide substance P promotes blood-brain barrier breaching by breast cancer cells through changes in microvascular endothelial cell tight junctions.

Authors:  Pedro L Rodriguez; Shuxian Jiang; Yigong Fu; Shalom Avraham; Hava Karsenty Avraham
Journal:  Int J Cancer       Date:  2013-09-03       Impact factor: 7.396

10.  Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells.

Authors:  Shahrzad Asadi; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Alexandra Miniati; Nikolaos Sismanopoulos; Magdalini Vasiadi; Bodi Zhang; Dimitrios Kalogeromitros; Theoharis C Theoharides
Journal:  J Invest Dermatol       Date:  2011-11-17       Impact factor: 8.551

View more
  6 in total

1.  Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability.

Authors:  Md Shafikur Rahman; Shikha Kumari; Shiva Hadi Esfahani; Saeideh Nozohouri; Srinidhi Jayaraman; Nihar Kinarivala; Joanna Kocot; Andrew Baez; Delaney Farris; Thomas J Abbruscato; Vardan T Karamyan; Paul C Trippier
Journal:  J Med Chem       Date:  2021-08-26       Impact factor: 8.039

Review 2.  Modeling the blood-brain barrier for treatment of central nervous system (CNS) diseases.

Authors:  Olivia Rice; Allison Surian; Yupeng Chen
Journal:  J Tissue Eng       Date:  2022-05-14       Impact factor: 7.940

3.  Identification and Characterization of Two Structurally Related Dipeptides that Enhance Catalytic Efficiency of Neurolysin.

Authors:  Srinidhi Jayaraman; Joanna Kocot; Shiva Hadi Esfahani; Naomi J Wangler; Arzu Uyar; Yehia Mechref; Paul C Trippier; Thomas J Abbruscato; Alex Dickson; Hideki Aihara; David A Ostrov; Vardan T Karamyan
Journal:  J Pharmacol Exp Ther       Date:  2021-08-13       Impact factor: 4.030

Review 4.  Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives.

Authors:  Manuele Figueiredo da Silva; João Xavier de Araújo-Júnior; Edeildo Ferreira da Silva-Júnior; Luana Heimfarth; Paulo Ricardo Martins-Filho; Jullyana de Souza Siqueira Quintans; Lucindo José Quintans-Júnior
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-28       Impact factor: 3.000

Review 5.  Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases.

Authors:  Xin Yi Yeo; Grace Cunliffe; Roger C Ho; Su Seong Lee; Sangyong Jung
Journal:  Biomedicines       Date:  2022-02-01

6.  The relationship between dietary total antioxidant capacity, clinical parameters, and oxidative stress in fibromyalgia syndrome: A novel point of view.

Authors:  Kübra Tel Adıgüzel; Özlem Köroğlu; Evren Yaşar; Arif Kenan Tan; Gülhan Samur
Journal:  Turk J Phys Med Rehabil       Date:  2022-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.